Polycythemia Vera

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Rita Xu	+ 651 word(s)	651	2020-12-15 07:35:22

Cite

If you have any further questions, please contact Encyclopedia Editorial Office.

Select a Style

Xu, R. Polycythemia Vera. Encyclopedia. Available online: https://encyclopedia.pub/entry/5388 (accessed on 21 September 2026).

Xu R. Polycythemia Vera. Encyclopedia. Available at: https://encyclopedia.pub/entry/5388. Accessed September 21, 2026.

Xu, Rita. "Polycythemia Vera" Encyclopedia, https://encyclopedia.pub/entry/5388 (accessed September 21, 2026).

Xu, R. (2020, December 24). Polycythemia Vera. In Encyclopedia. https://encyclopedia.pub/entry/5388

Xu, Rita. "Polycythemia Vera." Encyclopedia. Web. 24 December, 2020.

Polycythemia Vera

Edit

This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/condition/polycythemia-vera

Polycythemia vera is a condition characterized by an increased number of red blood cells in the bloodstream. Affected individuals may also have excess white blood cells and blood clotting cells called platelets. These extra cells and platelets cause the blood to be thicker than normal. As a result, abnormal blood clots are more likely to form and block the flow of blood through arteries and veins. Individuals with polycythemia vera have an increased risk of deep vein thrombosis (DVT), a type of blood clot that occurs in the deep veins of the arms or legs. If a DVT travels through the bloodstream and lodges in the lungs, it can cause a life-threatening clot known as a pulmonary embolism (PE). Affected individuals also have an increased risk of heart attack and stroke caused by blood clots in the heart and brain.

genetic conditions

References

Cario H, McMullin MF, Pahl HL. Clinical and hematological presentation ofchildren and adolescents with polycythemia vera. Ann Hematol. 2009Aug;88(8):713-9. doi: 10.1007/s00277-009-0758-y.
Delhommeau F, Jeziorowska D, Marzac C, Casadevall N. Molecular aspects ofmyeloproliferative neoplasms. Int J Hematol. 2010 Mar;91(2):165-73. doi:10.1007/s12185-010-0530-z.
Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A, Li CY,Ketterling RP, Tefferi A. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol. 2008Mar;80(3):197-200.
Landolfi R, Nicolazzi MA, Porfidia A, Di Gennaro L. Polycythemia vera. Intern Emerg Med. 2010 Oct;5(5):375-84. doi: 10.1007/s11739-010-0369-6.
Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferativeneoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600. doi:10.3109/10428194.2013.813500.
Tefferi A. Novel mutations and their functional and clinical relevance inmyeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.Leukemia. 2010 Jun;24(6):1128-38. doi: 10.1038/leu.2010.69.Review.
Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemiavera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol MaligRep. 2009 Jan;4(1):33-40. doi: 10.1007/s11899-009-0005-6.

©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Genetics & Heredity

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Rita Xu

View Times: 1.0K

Entry Collection: MedlinePlus

Update Date: 24 Dec 2020

Table of Contents

Video Upload Options

References